Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
about
HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples.Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy.Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy.
P2860
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Different HBsAg decline after ...... ative and genotype A, D and E.
@en
Different HBsAg decline after ...... ative and genotype A, D and E.
@nl
type
label
Different HBsAg decline after ...... ative and genotype A, D and E.
@en
Different HBsAg decline after ...... ative and genotype A, D and E.
@nl
prefLabel
Different HBsAg decline after ...... ative and genotype A, D and E.
@en
Different HBsAg decline after ...... ative and genotype A, D and E.
@nl
P2093
P2860
P356
P1476
Different HBsAg decline after ...... ative and genotype A, D and E.
@en
P2093
Antonio D'Avolio
Chiara Simona Cardellino
Giovanni Di Perri
Giuseppe Cariti
Lucio Boglione
P2860
P304
P356
10.1002/JMV.24038
P577
2014-08-08T00:00:00Z